Inefficient killing of quiescent human epithelial cells by replicating adenoviruses: Potential implications for their use as oncolytic agents

Cancer Gene Therapy

Volumn 12, Issue 8, 2005, Pages 691-698

  Vaillancourt, Mei Ting ^a,b   Atencio, Isabella ^a   Quijano, Erlinda ^a   Howe, John A ^a   Ramachandra, Murali ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Department of Pharmacology ^*  (United States)

Author keywords

Adenovirus; E2F; Infection; Oncolysis; Primary cells

Indexed keywords

ANTINEOPLASTIC AGENT; DL 01 07; DL 309; DNA; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ADENOVIRUS; ARTICLE; BREAST EPITHELIUM; CELL CULTURE; CELL KILLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; DNA REPLICATION; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS MUTANT; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CAPSID PROTEINS; CELLS, CULTURED; DNA, VIRAL; EPITHELIAL CELLS; GENE EXPRESSION; GENES, VIRAL; HUMANS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 22944490239     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700840     Document Type: Article

References (20)

1. Howe JA, Demers GW, Johnson DE. et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther. 2000;2:485-495.
2. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol. 2001;19:1035-1041.
3. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Therapy. 2001;8:89-98.
4. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic antitumoral efficacy. Nat Med. 2000;6:1134-1139.
5. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol. 2000;18:723-727.
6. Jones N, Shenk T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc Natl Acad Sci USA. 1979;76:3665-3669.
7. de Martin R, Raidl M, Hofer E, Binder BR. Adenovirus-mediated expression of green fluorescent protein. Gene Therapy. 1997;4:493-495.
8. Huyghe BG, Liu X, Sutjipto S, et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther. 1995;6:1403-1416.
9. Shabram PW, Giroux DD, Goudreau AM, et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther. 1997;8:453-465.
10. Atencio IA, Ramachandra M, Shabram P, Demers GW. Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines. Cell Growth Differ. 2000;11:247-253.
11. Wen SF, Xie L, McDonald M, et al. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Cancer Gene Ther. 2000;7:1469-1480.
12. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol. 2000;74:6147-6155.
13. Brightwell G, Poirier V, Cole E, et al. Serum-dependent and cell cycle-dependent expression from a cytomegalovirus-based mammalian expression vector. Gene. 1997;194: 115-123.
14. Brantley DM, Chen CL, Muraoka RS, et al. Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol Cell Biol. 2001;12: 1445-1455.
15. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
16. Branton P. Early gene expression. In: Seth P, ed. Adenoviruses: Basic Biology to Gene Therapy. Austin, TX: RG Landes; 1999: 33-58.
17. Doronin K, Toth K, Kuppuswamy M, et al. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology. 2003;305:378-387.
18. Tollefson AE, Scaria A, Hermiston TW, et al. The adenovirus death protein (E3-11.6K.) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J Virol. 1996;70: 2296-2306.
19. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol. 2004;273:291-334.
20. Smith RR, Huebner RJ, Rowe WP, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9:1211-1218.